Latest news
Experimental Menopause Drug Shows Promise Mid-Stage Trial, Reduces Hot Flashes By 83% - Health and MeHealth and Me · Tue, 11 Aug 2026 03:30:00 GMTAbCellera Stock Soars 41% on Hot-Flash Trial Data - Briefs FinanceBriefs Finance · Tue, 11 Aug 2026 02:03:09 GMTPositive results from the mid-stage trial of the hot flash treatment drug ABCL635, AbCellera Biologics (ABCL.US) surges in response - BitgetBitget · Tue, 11 Aug 2026 00:05:09 GMTAbCellera's hot flash antibody shows promise for once-monthly dosing - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 22:07:20 GMTType 2 Diabetes Linked to Worse Menopause Symptoms - HealthlineHealthline · Mon, 10 Aug 2026 20:01:24 GMTAbCellera (NASDAQ:ABCL) jumps 37.5% as hot-flash trial hits all main and secondary goals - TechStock²TechStock² · Mon, 10 Aug 2026 18:58:02 GMTAbCellera Jumps 32% After Menopause Drug Slashes Hot Flashes in Phase 2 Trial - finance.biggo.comfinance.biggo.com · Mon, 10 Aug 2026 18:07:00 GMTPhase 2 data: ABCL635 reduces frequency, severity of VMS symptoms - Contemporary OB/GYNContemporary OB/GYN · Mon, 10 Aug 2026 14:54:42 GMT